Is Denali Therapeutics Inc. (DNLI) halal? Not Halal. Based on AAOIFI screening, Denali Therapeutics Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Denali Therapeutics Inc.

DNLI: Is Denali Therapeutics Inc. Halal?

Not Halal

Denali Therapeutics Inc.

NASDAQHealthcareUS

$19.35

-5.19%

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector: Healthcare 路 Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026
F

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap1.0% / 30.0%

Compliance History

  1. Not Halalnow

    since Jun 2026

  2. Doubtful

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: FY 2025Source: EDGAR

Financial Overview

Market Cap

3.1B

Price

$19.35

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

00
0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

00
0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

00
0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

01
0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

01
0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

A

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

A

PFE

Pfizer Inc.

F

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+
Free 路 No credit card required

Track DNLI and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started FreeBrowse Screener
10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Denali Therapeutics Inc. (DNLI) halal to invest in?
Denali Therapeutics Inc. (DNLI) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Denali Therapeutics Inc. get a F compliance rating?
Denali Therapeutics Inc. (DNLI) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.0% (limit 30%); interest-bearing deposits of 23.3% (limit 30%); prohibited income of 12.98% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Denali Therapeutics Inc.'s Shariah verdict?
Denali Therapeutics Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Denali Therapeutics Inc. re-screened for Shariah compliance?
Denali Therapeutics Inc. (DNLI) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 路 For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.